



Announcement Summary

Entity name

NEUROTECH INTERNATIONAL LIMITED

Announcement Type

New announcement

Date of this announcement

10/4/2024

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	NTIPERR2 Performance Rights	50,000,000
NTI	ORDINARY FULLY PAID	10,000,000

Proposed +issue date

28/6/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

NEUROTECH INTERNATIONAL LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

73610205402

1.3 ASX issuer code

NTI

1.4 The announcement is

New announcement

1.5 Date of this announcement

10/4/2024

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	26/6/2024	Estimated	No

Comments

Subject to shareholder approval, NTI has agreed to issue 10 million ordinary shares to Fenix Innovation Group ("Fenix") (or its nominees) upon signing of a definitive agreement with Fenix and a total of 50 million performance rights to Fenix (or its nominees) subject to vesting conditions expected to result in significant value accretion for Neurotech, if successful. The shares will be subject to voluntary escrow restrictions for 12 months from date of issue. Refer to the ASX announcement released on the same day as this Appendix 3B for further information. The date for determination above is an estimate and is subject to change.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?
Existing class

Will the proposed issue of this +security include an offer of attaching +securities?
No

Details of +securities proposed to be issued

ASX +security code and description

NTI : ORDINARY FULLY PAID

Number of +securities proposed to be issued

10,000,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

**Please describe the consideration being provided for the +securities**

Part consideration for the entry into a strategic partnership with leading contract research organisation, Fenix Innovation Group. Refer to the ASX announcement released on the same day as this Appendix 3B for further information.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

New class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?

No

Will the entity be seeking quotation of the 'new' class of +securities on ASX?

No

ASX +security code

New class-code to be confirmed

+Security description

NTIPERR2 Performance Rights

+Security type

Performance options/rights

Number of +securities proposed to be issued

50,000,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Part consideration for the entry into a strategic partnership with Fenix and an equity-based incentive for Fenix over the course of their strategic collaboration with NTI. These performance rights are subject to vesting conditions expected to result in significant value accretion for Neurotech, if successful. Refer to the ASX announcement released on the same day as this Appendix 3B for further information.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

Performance options/rights details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.0000	28/6/2027

Details of the type of +security that will be issued if the option is exercised

NTI : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One Fully Paid Share (ASX:NTI).

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Refer to the ASX announcement released on the same day as this Appendix 3B. Please note the above expiry date is an estimate and will be dependent on the date of the Company's next shareholders meeting, as well as the date that is 3 years from the date of issue of these performance rights.

Part 7C - Timetable

7C.1 Proposed +issue date

28/6/2024

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

26/6/2024

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

Yes

7D.4a Please enter the number and +class of the +securities subject to +voluntary escrow and the date from which they will cease to be subject to +voluntary escrow

10 million shares are proposed to be issued subject to voluntary escrow restrictions for 12 months from date of their issue. As at the date of this Appendix 3B, the date of these shares' issue is unknown and will be dependent on the date of the next shareholders meeting held by the Company.



Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

No

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

N/A

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Consideration and equity-based incentive to Fenix Innovation Group under a Strategic Partnership with the Company.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

Refer to the ASX announcement released on the same day as this Appendix 3B for further information.

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)